Peptides for Fat Loss: What Did Human Trials Measure?

Some human trials of peptides for fat loss measured fat directly. But they measured different things: total body fat, fat inside the liver or fat around internal organs. Those findings cannot produce a trustworthy universal winner. The percentage with the biggest headline doesn't automatically get the trophy. For someone wondering whether midlife changes around the waist have a research-backed explanation, the useful question is narrower: which studies actually measured the kind of fat being discussed?

Retatrutide is the main example here, with human imaging research on liver fat. Tirzepatide offers a whole-body scanning comparison; tesamorelin brings a very specific medical population; MOTS-c marks the boundary between animal experiments and human findings. This selected evidence can explain what researchers observed. It cannot identify the best compound for an individual, establish menopause-specific outcomes or turn separate trials into a tested combination.

Research Confidence

★★★★☆ — Randomized human studies used scans to measure particular fat stores, including a retatrutide substudy involving 98 adults followed for 48 weeks. Confidence applies to those measured findings, not a universal ranking. Missing scans, different populations and absent menopause-specific analyses restrict how broadly the results apply. The selected MOTS-c evidence is preclinical.

Study Snapshot

• Study type: randomized, double-blind, placebo-controlled human substudy of retatrutide
• Participants: 98 adults; mean age 46.6 years; 46.9% female
• Duration: 48 weeks; main liver-fat assessment at week 24
• Measured: relative change in liver fat using MRI
• Found: liver fat changed −82.4% in the 12 mg group versus +0.3% with placebo at week 24
• Funding: Lilly-sponsored; employee/shareholder authors and other industry relationships disclosed

Why This Matters: Peptides for Fat Loss Measure Different Targets

A waistband, a bathroom scale and a liver scan describe different parts of the same body. Someone whose clothes fit differently may reasonably care about abdominal size; someone concerned about muscle may care about strength. Neither question is answered fully by a weight-loss percentage.

Body weight includes more than fat. Whole-body scans estimate fat and lean tissue. Visceral fat sits around internal organs; liver fat sits within the liver. These are distinct research targets.

For a clinical conversation, the useful distinction is what concern prompted the question: overall weight, abdominal fat, liver health or physical function. A sensible expectation starts with the outcome actually measured. Our guide to understanding research peptides explains the broader research context; the particular trial still determines what a finding means.

Retatrutide: following the question into the liver

The retatrutide investigation moved beyond the scale by asking what happened inside the liver. In Sanyal and colleagues' randomized human substudy, participants received investigational retatrutide injections of 1, 4, 8 or 12 mg under the skin weekly, or matching placebo. Random assignment determined the group; double-blinding meant participants and investigators did not know who received which intervention.

MRI let the team follow liver fat over time. The primary endpoint, the main result chosen in advance, concerned relative liver-fat change. The snapshot's −82.4% result means a reduction relative to starting liver fat. It does not mean participants lost that percentage of their body weight.

The team also examined abdominal fat. Those analyses were exploratory: additional questions rather than the main test the study was built around. The investigation therefore followed a useful path—from body weight to a particular fat store, then outward to related abdominal measurements.

Retatrutide remained investigational in the supplied regulatory records. Health Canada's April 2026 advisory named it among unauthorized injectable peptide drugs; the FDA's supplied communication identified it as unapproved in the United States.

Tirzepatide: whole-body fat and lean tissue both changed

Whole-body fat is closer to what many people mean when searching for the best peptides for fat loss. Look and colleagues' randomized, double-blind, placebo-controlled human substudy used DXA, a scan that estimates fat and lean tissue.

Over 72 weeks, participants received tirzepatide injections of 5, 10 or 15 mg under the skin weekly, pooled for analysis, or placebo. Both groups received lifestyle counselling. Of 255 enrolled participants, 160 entered the efficacy analyses—the analyses used to estimate the intervention's effects.

Fat mass changed −33.9% with tirzepatide versus −8.2% with placebo: a difference of 25.7 percentage points. The reported uncertainty range was 20.0 to 31.4 percentage points greater reduction. Lean mass also decreased.

For someone concerned about staying strong, the next question is physical function. DXA estimates lean tissue; researchers need strength tests to establish how strong someone remains. That distinction also matters when reading about recovery research.

A leaderboard built from liver-fat percentages and whole-body-fat percentages deserves to be retired. These papers measured different targets. Sorting their numbers from largest to smallest gives the spreadsheet a winner, not the reader an answer.

Tesamorelin and MOTS-c: population and species change the answer

The search for peptides for belly fat loss often reaches tesamorelin. FDA prescribing information reports two randomized, double-blind, placebo-controlled human trials involving 412 and 404 adults with HIV-associated lipodystrophy, a condition involving altered fat distribution.

The trials used the original EGRIFTA formulation, 2 mg injected under the skin daily for 26 weeks. Visceral-fat area differed from placebo by −31 cm² and −21 cm². These are cross-sectional areas, not kilograms. The FDA indication concerns excess abdominal fat in that population and expressly excludes general weight-loss management.

For those searching for the best peptides for visceral fat loss, that population belongs beside the result.

MOTS-c sits in a different evidence category. Lee and colleagues' animal experiment used eight-week-old male CD-1 mice, with figure-reported N=10. Researchers injected synthetic MOTS-c into the abdominal cavity at 0.5 mg/kg/day for eight weeks, comparing it with vehicle, the carrier without the peptide.

Under high-fat feeding, mice gained less weight without eating fewer calories. Under normal feeding, the authors reported no body-weight effect. This was an animal outcome. Health Canada's supplied advisory also named MOTS-c among unauthorized injectable peptide drugs.

What This Tells Us About Women Specifically: Midlife Participation Was Not Menopause Research

Women accounted for 46.9% of the retatrutide substudy and 73.1% of the tirzepatide analysis. Calculated from the reported male proportions, women represented 14% and 16% of the tesamorelin trials. The selected MOTS-c experiment used only male mice.

None reported menopausal status in the retained evidence, and the brief does not establish adjustment for hormone therapy. Retatrutide and tesamorelin did not supply sex-separated outcomes; tirzepatide included exploratory analyses by sex.

Searches for fat loss peptides for women therefore need a further distinction: including women around midlife does not answer whether outcomes differ before and after menopause. The same trials remain informative for men within their studied populations.

Research Use And Availability

Nuforme supplies retatrutide as a research material in Canada. Its research-use-only designation is not an authorization for human consumption or evidence of equivalence to trial medication. Health Canada states that research-use labelling does not exempt unauthorized peptide drugs from regulatory requirements. The supplied catalogue information does not establish additional batch-testing or purity claims here.

Final Thoughts: The Most Relevant Result Depends on the Fat Being Measured

For whole-body fat, the retained tirzepatide scan study answers the closest question; retatrutide addresses liver fat, and tesamorelin addresses visceral fat in HIV-associated lipodystrophy.

The concrete edges matter. Retatrutide's week-48 MRI data were missing for 56.1%; 77.6% completed the substudy. There were no liver biopsies. Gastrointestinal events predominated, and two retatrutide participants had serious adverse events. Tirzepatide's substudy lacked a standalone adverse-event analysis; missing scans cannot be counted as treatment dropouts. Tesamorelin trial completion was 80% and 74%; its label warns about glucose intolerance, fluid retention and elevated IGF-1. Both newer imaging substudies had Lilly involvement.

A direct comparison using the same scans, comparable populations and more complete follow-up would make the answer broader. Today, the useful result is a specific fat measurement in a specific population.